IL286680A - A drug to treat cancer - Google Patents

A drug to treat cancer

Info

Publication number
IL286680A
IL286680A IL286680A IL28668021A IL286680A IL 286680 A IL286680 A IL 286680A IL 286680 A IL286680 A IL 286680A IL 28668021 A IL28668021 A IL 28668021A IL 286680 A IL286680 A IL 286680A
Authority
IL
Israel
Prior art keywords
medicament
treating cancer
cancer
treating
Prior art date
Application number
IL286680A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of IL286680A publication Critical patent/IL286680A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL286680A 2019-04-01 2021-09-26 A drug to treat cancer IL286680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019070120 2019-04-01
PCT/JP2020/014832 WO2020204033A1 (ja) 2019-04-01 2020-03-31 がん治療用医薬

Publications (1)

Publication Number Publication Date
IL286680A true IL286680A (en) 2021-10-31

Family

ID=72668636

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286680A IL286680A (en) 2019-04-01 2021-09-26 A drug to treat cancer

Country Status (10)

Country Link
US (1) US20220193064A1 (https=)
EP (1) EP3949990A4 (https=)
JP (1) JP7549889B2 (https=)
KR (1) KR20210144767A (https=)
CN (1) CN113660954B (https=)
AU (1) AU2020255907A1 (https=)
CA (1) CA3135157A1 (https=)
IL (1) IL286680A (https=)
TW (1) TWI862564B (https=)
WO (1) WO2020204033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230398227A1 (en) * 2020-10-05 2023-12-14 Chiome Bioscience Inc. Medicine for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
CN1304046C (zh) * 2004-06-29 2007-03-14 上海人类基因组研究中心 肝癌相关基因dlk1及其应用
KR101512203B1 (ko) * 2006-11-10 2015-04-15 가부시키가이샤 리부텍쿠 in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체
US8017118B2 (en) * 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
JPWO2014017524A1 (ja) 2012-07-26 2016-07-11 デンカ株式会社 樹脂組成物
WO2014054820A1 (ja) * 2012-10-03 2014-04-10 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
HUE056289T2 (hu) * 2017-02-08 2022-02-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok

Also Published As

Publication number Publication date
TWI862564B (zh) 2024-11-21
CA3135157A1 (en) 2020-10-08
WO2020204033A1 (ja) 2020-10-08
EP3949990A4 (en) 2023-02-08
EP3949990A1 (en) 2022-02-09
CN113660954B (zh) 2025-01-14
CN113660954A (zh) 2021-11-16
JP7549889B2 (ja) 2024-09-12
US20220193064A1 (en) 2022-06-23
TW202104259A (zh) 2021-02-01
AU2020255907A1 (en) 2021-10-28
JPWO2020204033A1 (https=) 2020-10-08
KR20210144767A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
IL287907A (en) Cancer treatment methods
PT3431105T (pt) Composição medicinal para tratamento de cancro
GB201903546D0 (en) Cancer treatment
EP3892282A4 (en) COMBINATIONS FOR TREATING CANCER
IL281439A (en) Combined treatment for blood cancer
IL282093A (en) Combination therapy for cancer
IL275949A (en) Combined treatment for the treatment of cancer or its prevention
GB201905780D0 (en) Cancer therapy
IL287652A (en) Cancer treatment
IL289213A (en) A pharmaceutical preparation for tumor treatment
IL276074A (en) Combined treatment for the treatment of cancer or its prevention
GB201909468D0 (en) Compounds for treating cancer
IL285466A (en) Cancer treatment
SG11202010528XA (en) Combinations for treating cancer
IL276073A (en) Combined treatment for the treatment of cancer or its prevention
IL275860A (en) Combined treatment for the treatment of cancer or its prevention
IL286680A (en) A drug to treat cancer
IL288035A (en) Cancer treatment
GB201909466D0 (en) Compounds for treating cancer
HK40080960A (en) Combination therapy for treating cancer
GB201910644D0 (en) Cancer Treatment
GB201907149D0 (en) Cancer treatment
HK40054682A (en) Combination therapy for treating cancer
HK40054677A (en) Combination therapy for treating cancer
ZA202100843B (en) Conjugate for treating cancer